CLAIMS

1. A composition comprising a population of culture expanded genetically unmodified [STRO-1+] mesenchymal precursor cells (MPCs) in which the culture expanded cells express angiopoietin-1 (Ang1) and vascular endothelial growth factor (VEGF) at a ratio [Ang1:VEGF] between 2:1 and 30:1.

2. A composition according to Claim 1, in which the MPCs express Ang1:VEGF at a ratio between 5:1 and 20:1.

3. A composition according to Claim 1 or 2, in which the MPCs express Ang1 in an amount between 0.1 $\mu g/10^6$ cells and 1.0 $\mu g/10^6$ cells.

4. A composition according to Claim 1, 2 or 3, in which the MPCs express Vascular Endothelial Growth Factor (VEGF) in an amount less than 0.05 $\mu g/10^6$ cells.

5. A composition according to Claim 1, 2 or 3, in which the MPCs express VEGF in an amount less than 0.03 $\mu g/10^6$ cells.

6. A method for obtaining genetically unmodified stem cells suitable for use in promoting vascularisation and/or angiogenesis, comprising:

obtaining at least one cell population including stem cells from at least one donor;

culturing the stem cells;

determining the amount of Ang1 and VEGF expressed by the stem cells in each of said at least one cell population(s); and

selecting stem cells which express Ang1 and VEGF at a ratio [Ang1:VEGF] between 2:1 and 30:1.

7. A method according to Claim 6, in which the stem cells which express Ang1:VEGF at a ratio of at least 10:1, at least 20:1 or at least 30:1 are selected.

8. Use of a composition according to any of Claims 1 to 5, for promoting vascularization promoting angiogenesis and/or treating a condition in which increased Ang1 expression is desirable.

9. A method for promoting vascularization, promoting angiogenesis and/or treating a condition in which increased Ang1 expression is desirable in a subject, the method comprising administering a composition according to any of Claims 1 to 5 to a subject.

10. A composition according to any of Claims 1 to 5, in which the MPCs are produced by culture expanding a population of MPCs *in vitro*, in which the culture expanding comprises:

culturing a population of MPCs in a cell culture medium, in which the cell culture medium contains a short acting L-ascorbic acid derivative but does not contain a substantial amount of a long acting L-ascorbic acid derivative; and/or

is supplemented with less than 10% v/v fetal calf serum (FCS); and/or

is supplemented with non-fetal serum.

11. Use of a composition according to any of Claims 1 to 5 and 10, or a method according to Claim 6 or 7 in the manufacture of a medicament for promoting vascularisation, promoting angiogenesis and/or treating a condition in which increased Ang1 expression is desirable.

12. A method according to Claim 6 or 7, in which the cell culture media is supplemented with:

non-fetal serum;

neo-natal serum;

NBCS;

human neo-natal serum;

non-fetal adult serum; or,

human adult serum.

CLAIMS

1. A composition comprising a population of culture expanded genetically unmodified stem cells in which the culture expanded cells express angiopoietin-1 (Ang1) and vascular endothelial growth factor (VEGF) at a ratio [Ang1:VEGF] between 2:1 and 30:1.

2. A composition according to Claim 1, in which the stem cells express Ang1:VEGF at a ratio between 5:1 and 20:1.

3. A composition comprising a population of culture expanded genetically unmodified stem cells in which the culture expanded cells express vascular endothelial growth factor (VEGF) in an amount of at least 0.05 $\mu g/10^6$ cells.

4. A composition according to Claim 1, 2 or 3, in which the stem cells are mesenchymal stem cells.

5. A composition according to any preceding claim, in which the stem cells are mesenchymal precursor cells.

6. A composition according to any preceding claim, further comprising an acceptable pharmaceutical carrier.

7. An *in vitro* method for culture expanding stem cells, the method comprising:

culturing a population of stem cells in a cell culture media, in which the cell culture media contains:

a L-ascorbic acid salt; and/or

non-fetal serum.

8. A method according to Claim 7, in which the L-ascorbic acid salt is L-ascorbic acid sodium salt.

9. A method according to Claim 7 or 8, in which the cell culture media is supplemented with at least about 5% v/v FCS.

10. A method according to Claim 7, 8 or 9, in which the non-fetal serum is new born calf serum (NBCS).

11. A method according to Claim 10, in which the cell culture media contains NBCS at a level of at least 2% v/v.

12. A method according to Claim 10, in which the cell culture media contains NBCS at a level of at least 5% v/v.

13. A method according to Claim 10, 11 or 12, in which the cell culture media is supplemented with a mixture of NBCS and FCS.

14. A method according to Claim 13, in which the ratio of NBCS to FCS is about 1:1.

15. A method according to Claim 13, in which the media is supplemented with 5% v/v FCS and 5% v/v NBCS.

16. Use of a composition of any one of Claims 1 to 6 for promoting vascularisation and/or angiogenesis.